Theralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the treatment of the Herpes Simplex Virus in an animal model. TORONTO, ON / ...

Italian pharma Alfasigma has penned a 125 million euro ($145 million) deal for the rights to an injectable form of an investigational herpes simplex virus (HSV) encephalitis treatment. | Italian ...

For the first time, scientists have captured how new antiviral drugs halt the herpes virus in real time as it tries to replicate.

Even though genital herpes is fairly common (roughly one in six Americans has it, according to the Centers for Disease Control & Prevention [CDC]), it's highly stigmatized, in large part because ...

Members of a new class of antivirals are being tested in U.S. clinical trials, and one has gained approval in Japan, but how ...

Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus FDA-approved, standard of care treatments Acyclovir and Abreva in a preclinical animal model. In the ...

Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical company, and Innovative Molecules GmbH ("Innovative Molecules"), a clinical-stage biotechnology company, today announced a strategic partnership ...

Assembly Biosciences, Inc. (NASDAQ:ASMB) released interim pharmacokinetic (PK) and safety results from healthy participants in the Phase 1a portion of its ongoing Phase 1a/b study of ABI-5366, an ...

BALA CYNWYD, PA, USA, September 15, 2023/EINPresswire.com/ -- A new advocacy effort is driving change as patients living with herpes globally are rallying for a cure ...

Herpes probably isn't a word you expected to hear during pregnancy – and if it is, you might be feeling nervous, confused, or ...

Theralase® validates previous University of Manitoba research by demonstrating that Ruvidar TM is safe and effective in the treatment of the Herpes Simplex Virus in an animal model. Herpes Simplex ...